Purpose of review Treatment with combination antiretroviral therapy during pregnancy reduces the chance of mother to child transmission of HIV. Physiological changes during pregnancy can lead to lower exposure to antiretrovirals, possibly resulting in virological failure. For most antiretrovirals, data on exposure during pregnancy and transplacental passage are limited. This review summarizes the most recent information on pharmacokinetics (including transplacental passage), efficacy, as well as the safety of antiretrovirals during pregnancy.
INTRODUCTION
Treatment with antiretrovirals, especially when used as combination antiretroviral therapy (cART), dramatically reduces the chance of mother to child transmission (MTCT) of HIV from 20% to less than 1%. Current perinatal guidelines recommend to start cART at 12-14 weeks of pregnancy, or earlier in the case of a CD4 cell count below 350-500 cells/ ml. Preferred agents to include in cART are lamivudine, zidovudine, nevirapine, ritonavir-boosted lopinavir or atazanavir/r [1,2] according to the US Department of Health & Human Services (DHHS) and British HIV Association guidelines, or triple therapy including nevirapine or efavirenz [3] may be used according to the WHO guidelines.
Physiological changes occurring during pregnancy can alter exposure to drugs. Examples include increased gastric pH, volume of distribution, glomerular filtration and cardiac output, decreased protein binding and alteration of cytochrome P450 activity.
Recently, a meta-analysis of these changes during pregnancy was published [4 & ]. The changes lead to lower exposure to antiretrovirals during (late) pregnancy in most cases. In turn, subtherapeutic drug levels could lead to virological failure and development of resistant virus and eventually to MTCT of HIV. In some studies, antiretroviral dose was increased in the third trimester of pregnancy to compensate for lower maternal exposure. Also, therapeutic drug monitoring (TDM) is recommended to check antiretroviral levels and perform dose increases on an individual level. Besides considerations with regard to maternal exposure, antiretrovirals can pass the blood-placenta barrier and might cause teratogenicity, induce premature birth or cause low birth weight. Yet, placenta passage of antiretrovirals can also ensure infant preexposure prophylaxis.
During clinical development exposure of pregnant women to new drugs is avoided, whereas after reaching the market it will be used by pregnant women. Hence, postmarketing studies are being performed focusing on pharmacokinetics during pregnancy, including transplacental passage. Also, the effects of antiretroviral use on MTCT, preterm delivery and teratogenicity are important issues here.
We now give an update of the most recent (since 2012) publications on these topics.
PHARMACOKINETICS AND EFFICACY OF ANTIRETROVIRALS DURING PREGNANCY
An extensive review has recently been published [5 && ], covering pharmacokinetic studies on antiretrovirals in pregnancy until 2012. This earlier review concluded that, to optimize antiretroviral therapy during pregnancy, pharmacological changes during pregnancy and transplacental transfer should be taken into account. TDM of antiretroviral exposure in pregnant women was mentioned as an intervention to optimize therapy.
Two other reviews were published in 2012 on this subject [6, 7] . Furthermore, Eley et al. [8 & ] published a meta-analysis of pharmacokinetic data of atazanavir during pregnancy .
In the following section, an overview of recent studies published on pharmacokinetics and efficacy of antiretrovirals during pregnancy is given for each antiretroviral class; a summary of the results and conclusions can be found in Table 1 
Nucleoside/nucleotide reverse transcriptase inhibitors
Two intensive-sampling pharmacokinetic studies, collecting pharmacokinetic curves during pregnancy (second and/or third trimester) and postpartum (in the same women), were published: emtricitabine [9] was described by the IMPAACT group and tenofovir and emtricitabine pharmacokinetics by the PANNA network [10 & ]. Both studies observed decreased exposure (by approximately 25%) to these nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) during pregnancy, but conclude that dose adaptation seems not to be necessary during pregnancy. This conclusion was based on absence of an association with virological failure or MTCT [10 & ], or C 24h exceeding the IC 50 in all individuals [9] . The clinical relevance of IC 50 is uncertain, as it only reflects 50% inhibitory concentrations, whereas 100% inhibition of the virus is the aim in vivo.
Benaboud et al. reported two populationpharmacokinetics studies, describing lamivudine [11 & ] and tenofovir [12 & ] in pregnancy. The developed population-pharmacokinetic models were based on blood samples obtained just before dosing (C trough ) of pregnant women and nonpregnant women (controls).
The lamivudine exposure observed was close to the exposure of nonpregnant women and no dosage adjustment was advised [11 & ]. For tenofovir, a 39% increase of clearance was observed during pregnancy. To guarantee similar C trough as nonpregnant adults, an increase in tenofovir dose should be considered for women from the second trimester to delivery [12 & ]. A strength of these studies is that they use TDM data of nonpregnant HIV-infected women as control, and not only reference values in literature that are mostly based on pharmacokinetic studies in male patients or healthy volunteers. No information was given on MTCT and dosing advice was based on a (not yet clinically validated) population-pharmacokinetic model.
Non-nucleoside reverse transcriptase inhibitors
An intensive-sampling pharmacokinetics study was published on the pharmacokinetics of efavirenz 600 mg daily (q.d.) during pregnancy. Cressey et al. [13 && ] compared second and third trimester efavirenz pharmacokinetics curves to postpartum curves of the same patients (n ¼ 25). This is of great interest because WHO treatment guidelines include efavirenz, tenofovir and emtricitabine as triple therapy to be used during pregnancy.
They found a slight increase of oral clearance and decreased predose and C trough concentrations in
KEY POINTS
Physiological changes during pregnancy lead to lower exposure to antiretrovirals in most cases, especially for protease inhibitors.
The mechanism of transplacental passage should be a subject of future research.
Adding raltegravir to cART seems an option for women presenting with HIV in late pregnancy.
Exposure to new antiretrovirals (and efavirenz) during pregnancy and transplacental passage should be subjects of future research, also in resourcelimited settings. the third trimester. Efavirenz exposure during pregnancy after standard dosing remained in the therapeutic range. A limitation of this study is that the majority of patients were Thai (83%), and one MTCT took place, without known reason. These pharmacokinetic data support the use of standard efavirenz dosing during pregnancy.
Protease inhibitors
Calza et al. [14] compared trough lopinavir concentrations of the 400/100 mg lopinavir/r tablet in pregnant women (n ¼ 21) vs. nonpregnant women (n ¼ 20). In this study, a slight but nonsignificant decrease in lopinavir C trough was found during the third trimester of pregnancy. Only virologically suppressed women could take part, possibly excluding women with subtherapeutic lopinavir levels. Furthermore, the number of patients included was very low for interindividual comparisons. Else et al.
[15] compared the exposure of lopinavir soft gel capsules (SGCs) with the melt-extruded tablet during pregnancy. Despite a significant reduction in exposure during late pregnancy, the tablet formulation showed adequate concentrations (and higher than the SGC).
Patterson et al. [16] reported changes of unbound lopinavir plasma concentrations during different stages of pregnancy. The dose of lopinavir/r was empirically increased to 500/125 mg twice daily (b.i.d.) after week 30 of pregnancy. Pharmacokinetic curves were collected (n ¼ 12), at second and third trimester (400/100 mg and 500/125 mg b.i.d.) and postpartum. A less-than-proportional increase in exposure was seen after dose increase; the reason is not clear. Lopinavir free fraction did not significantly change during the second and third trimesters or postpartum, regardless of dose. Fayet-Mello et al. [17] also described free lopinavir plasma concentrations during pregnancy. They performed sparse sampling during pregnancy and postpartum in 42 women using 400/100 mg lopinavir/r. Total lopinavir concentrations were moderately decreased during pregnancy (31-39%), whereas unbound concentrations were not significantly altered (lopinavir free fraction was higher during pregnancy). Unbound lopinavir concentrations (but not the total concentrations) reported in the studies differ to some extent. This difference might be due to different analysis methods. Patterson et al. [16] used a rapid equilibrium dialysis, whereas Fayet-Mello et al. [17] used ultrafiltration. Furthermore, the unbound concentrations were close to the lower limit of quantification and could possibly be less accurate.
All studies mentioned above conclude that for treatment-naive patients with type virus, a dose Concentrations reported were converted to mg/l for the purpose of consistency.
/r, ritonavir boosted; APV, amprenavir; ARV, antiretroviral; AUC, area under the curve; b.i.d., twice daily; CC, case control; CI, confidence interval; CV, coefficient of variation; EFV, efavirenz; FPV, fosamprenavir; FTC, emtricitabine; GM, geometric mean; GMR, geometric mean ratio; IDV, indinavir; IQR, inter-quartile range; IS, intraindividual comparison; LPV, lopinavir; MTCT, mother to child transmission; MVC, maraviroc; n, number; PI, protease inhibitors; PK, pharmacokinetics; q.d., once daily; SD, standard deviation; TDF, tenofovir disoproxil; TFV, tenofovir.
increase of lopinavir is not necessary during pregnancy (using the tablet formulation). However, for treatment-experienced patients, generally needing higher antiretroviral concentrations, TDM during pregnancy is advised [15] . Atazanavir has been upgraded to the preferred agent for use during pregnancy in the July 2012 revised DHHS perinatal guidelines [1]. Similar to other protease inhibitors, lower exposure during pregnancy has been reported for atazanavir. This is also described in the current product characteristics of atazanavir [24] .
A systematic review reports results of 13 studies performed on atazanavir during pregnancy upto April 2012 [8 & ]. Pharmacokinetic studies (nine) as well as studies on safety and efficacy were reported, including one study with an increased dose during the third trimester (400/100 mg q.d. atazanavir/r). The increased dose resulted in therapeutic concentrations, but also a doubling of maternal grade 3-4 hyperbilirubinaemia. As current cART includes compounds that possibly reduce atazanavir C 24h (i.e. tenofovir), a dose increase during the third trimester may be required. If available, TDM is recommended to guide dose adaptations.
Recently, an intensive-sampling pharmacokinetic study applying higher atazanavir/r doses during pregnancy was published [18 & ]. Pharmacokinetic curves were recorded in the second trimester (300/100 mg q.d.), third trimester after dose increase to 400/100 mg q.d. and postpartum at the original dose. Postpartum atazanavir levels were higher than in nonpregnant adults. After dose increase, median atazanavir area under the curve (AUC) was similar to that seen in nonpregnant historical controls taking the standard dose. Concomitant tenofovir use seemed to reduce atazanavir exposure during the second and third trimester. These data suggest that a higher atazanavir /r dose should be used in the third trimester of pregnancy and is also to be considered during the second trimester, especially when tenofovir is coadministered and no TDM is available. A study with fosamprenavir/r 700/100 mg b.i.d. in pregnant women, performing intensive-sampling pharmacokinetics in the second (n ¼ 6) and third (n ¼ 9) trimester and 4 weeks postpartum (n ¼ 9), was reported [19 & ]. Amprenavir exposure was significantly lower in the second (35% lower) and third trimester (25% lower). For all patients, viral load at delivery was less than 200 copies/ml and no MTCT was observed. Therefore, dose adjustment does not seem to be required for fosamprenavir/r b.i.d. administration during pregnancy. However, in pregnant women with significant protease inhibitor mutations, close virologic monitoring is suggested with the use of fosamprenavir.
A prospective, intensive-sampling pharmacokinetic study of indinavir/r 400/100 mg b.i.d. in Thai pregnant women was performed by Cressey et al. [20 & ]. Pharmacokinetic curves were collected in the second (n ¼ 13) and third trimester (n ¼ 26) and postpartum (n ¼ 26). During pregnancy indinavir exposure was significantly reduced and approximately 30% of women did not achieve a target C trough (0.1 mg/l), and none did postpartum. Nineteen percent of the women had a viral load of more than 40 copies/ml at delivery; no vertical transmission occurred. Increasing the dose of indinavir/r during pregnancy to 600/100 mg b.i.d. may be preferable to ensure adequate drug concentrations. No analysis was done linking high viral loads and plasma concentrations.
A study with limited pharmacokinetics sampling during the second and third trimesters, and 6 weeks postpartum was done in 16 pregnant women receiving 1250 mg nelfinavir b.i.d. [21] . Pharmacokinetic analysis of total and unbound nelfinavir and the M8 metabolite was performed. Compared with postpartum, AUC of total nelfinavir was reduced by 46% in the third trimester, total M8 by 83%, free nelfinavir by 39% and free M8 by 79%. Despite this major reduction in exposure, no MTCT occurred. No dose recommendation was given on the basis of this finding, as the number of patients in the study was low and only limited sampling was performed.
Zorrilla et al. [22 & ] published a study with intensive-sampling (second and third trimester and postpartum) in 11 women using darunavir/r 600/100 mg b.i.d. The AUC 0-12h for total darunavir was 17-24% lower during pregnancy than postpartum; for unbound darunavir, the AUC 0-12h was only 7-8% lower during pregnancy (n ¼ 6). All 12 infants were HIV-negative. The authors suggest that, because of the nonclinically relevant change in unbound (active) darunavir, dose adjustment is not required for pregnant women receiving darunavir/r 600/ 100 mg b.i.d.
In addition, a case has been reported of a pregnant woman failing on 600/100 mg darunavir/r b.i.d. in late pregnancy. Darunavir C trough values were lower than expected and etravirine (200 mg b.i.d.) and maraviroc (150 mg b.i.d.) were added to darunavir/r to ensure adequate treatment [25 & ].
Integrase inhibitors
Croci et al. [26] described a case of a woman using lopinavir/r b.i.d. and raltegravir 400 mg b.i.d. during pregnancy. In the third trimester, a raltegravir C trough of 0.21 mg/l was reported. The baby was born not HIV-infected at 39 weeks gestational age. Exposure, based on a single trough sample, to raltegravir in the third trimester was similar to nonpregnant historical controls in this case. More pharmacokietics studies are needed to confirm this finding.
Entry inhibitors
In 2013, a poster was presented by the IMPAACT group and PANNA network at CROI 2013 describing the first intensive-sampling pharmacokinetic data during pregnancy, including placenta passage information. Maraviroc exposure during pregnancy (third trimester) was 21% lower than postpartum (n ¼ 9). To make valid dosing recommendations, more data are needed [23] .
TRANSPLACENTAL PASSAGE
An extensive review was published in 2011, covering information available on transplacental passage of antiretrovirals as well as concentrations in amniotic fluid [27] . Most of the studies described in the pharmacokinetics section of this review also assessed transplacental passage. The results are summarized in Table 2 .
Two recent articles described transplacental passage. Van Hoog et al. [28] summarized information on transplacental passage collected between 2003 and 2010 for nevirapine, nelfinavir and lopinavir.
Transplacental passage is not only influenced by physical-chemical properties of drugs, but drug transporters located in the placenta also can play a role in the passage of drugs across the placenta. The current knowledge on expression and function of ABC and SLC transporters in the trophoblast has been summarized [29 && ]. Olagunju et al. [30] reviewed potential effects of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. The potential of single nucleotide polymorphisms in transplacental passage was described in detail for nevirapine, efavirenz, lopinavir and atazanavir, as well as raltegravir. There is still insufficient knowledge about the pharmacogenetics possibly influencing antiretroviral exposure in pregnant women.
SAFETY OF ANTIRETROVIRAL USE DURING PREGNANCY
In general, a doubling of the percentage of preterm births (<37 weeks gestational age) is seen in HIVinfected women compared with non-HIV infected women. Whether this is due to HIV infection, the use of cART in general, or more specifically the use of protease inhibitors, is not clear. An analysis over time (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) indicates that the use of cART seems to contribute to this increase, as the percentage of prematurity in HIV-infected women was higher in 2005-2009 (routine, mainly protease inhibitor based cART) than in 1990-1993 (no therapy) [31] .
As treatment duration during pregnancy increases (also in resource-limited settings), the issue of risks of adverse effects of cART during pregnancy (such as prematurity and congenital abnormalities) is becoming more important. Western countries do have facilities to handle prematurity, but in resourcelimited settings this might be an important safety issue. Some articles warn about these safety concerns when implementing the new WHO guidelines to treat all HIV-infected patients (also during pregnancy) with efavirenz [32, 33] .
A prospective study (in the US) in 183 HIVinfected pregnant women, all using cART, reported that the increase of small-for-gestational-age (SGA) births (compared with the non-HIV infected population) in pregnant women with HIV is related to the severity of HIV disease and not to antiretroviral therapy [34] . As there was no control group (without cART), it is unclear how this conclusion could be drawn.
In French cohorts (n ¼ 13 271), a remarkable increase was reported in premature deliveries when regimens recommended in pregnancy changed: 9.2% during 1990-1993 (no therapy), 9.6% during 1994-1996 (mostly zidovudine monotherapy) to 12.4% during 1997-1999 (dual-nucleoside analogue therapy) and 14.3% during [2005] [2006] [2007] [2008] [2009] (routine cART therapy) [31] . Prematurity was associated with cART, compared with zidovudine monotherapy, when accounting for other factors. In 2005-2009, the prematurity rate was higher with boosted than with nonboosted protease inhibitor therapy (14.4 vs. 9.1%). It should be noted that the nonboosted protease inhibitor used was nelfinavir and the majority of the patients using boosted protease inhibitor used lopinavir/r.
Birth defects in pregnancies with exposure to antiretroviral drugs in Italy (1257 pregnancies) were reported over 2001-2011 [35] . A birth defect prevalence of 3.2% for exposure during the first trimester was found (compared with 3.4% for no antiretroviral exposure during the first trimester). No associations were found between birth defects and antiretroviral therapy, main drug classes or individual drugs. Preterm delivery occurred in 20.9% of pregnancies.
Nucleoside reverse transcriptase inhibitors
Possible renal and bone/growth problems in newborns, exposed intrauterinally have been investigated in several articles, recently. With the use of tenofovir as preexposure prophylaxis, conceptions during tenofovir use might increase.
Two articles report tenofovir use to be well tolerated during pregnancy. Pregnancies and infant outcomes of the DART trial (Uganda/Zimbabwe, period 2003-2009) have been described [36 && ]. There was no evidence that tenofovir exposure during the intrauterine period (n ¼ 111) had any adverse effects on pregnancy outcomes or on congenital, renal, bone or growth abnormalities up to 4 years of age.
In a prospective study, bone status of infants exposed to antiretrovirals (n ¼ 38) was compared with bone status of unexposed children from HIVnegative mothers (n ¼ 94) [37] . Antiretroviral exposure in utero seems not to negatively affect bone metabolism and bone development, and changes in bone quantitative ultrasonography measurements during the first year of life in antiretroviral-exposed individuals are similar to those occurring in healthy controls.
No difference was seen between bone development of infants intrauterinally exposed to tenofovir (n ¼ 15) and not exposed to tenofovir (n ¼ 23). Only a small group of children was exposed to tenofovir, and follow-up was only 1 year; however, a sensitive method quantifying bone status was used.
In contrast, Siberry et al. [38] found a lower mean height (0.41 cm shorter) and head circumference (0.32 cm smaller) at 1 year of age for infants exposed to tenofovir in utero (n ¼ 449) vs. infants exposed to a nontenofovir-containing regimen (n ¼ 1580), independent of early and late exposure in pregnancy. The significance of this finding is uncertain, but this underscores the need for studies with a sufficiently large number of patients.
Non-nucleoside reverse transcriptase inhibitors
Because of the increased risk of potentially lifethreatening hepatotoxicity in women with high CD4
þ cell counts, nevirapine should be started in pregnant women with CD4 þ cell counts more than 250 cells/ml only if benefit clearly outweighs risk [1] .
A systematic review and meta-analysis of the safety of nevirapine use during pregnancy was performed [39 & ]. The analysis included 20 studies representing 3582 pregnant women. Adverse events reported were severe hepatotoxicity (3.2%) and severe rash in 3.3% of patients. Around 6% of the patients discontinued nevirapine due to an adverse event. Pregnant women with a high CD4 þ cell count may be at an increased risk of adverse events, but evidence supporting this association is weak.
Efavirenz is suspected to cause teratogenicity based on animal studies and retrospective case reports showing that efavirenz may be associated with neural tube and/or central nervous system abnormalities. As WHO treatment guidelines include efavirenz, tenofovir and emtricitabine as triple therapy during pregnancy, safety information on the use during pregnancy is important. The US Antiretroviral Pregnancy Registry (APR) did not find an increased prevalence of overall birth defects with first-trimester efavirenz exposure compared with the overall US population.
A case report of bilateral oblique clefts and extremity anomaly in an infant after intrauterine efavirenz exposure was recently published [40] . The mother used efavirenz (along with atorvastatin) at the time of conception until 5 weeks postconception, when she switched to nelfinavir and zidovudine/lamivudine. The relation between efavirenz exposure and this congenital anomaly cannot be confirmed, nor rejected.
Protease inhibitors
Results of the APR were published in 2012 [41] , with more than 200 first trimester exposures to atazanavir reported (the threshold for performance of comparative analyses). A total of 698 pregnant women were exposed, 425 in the first trimester. Rates of birth defects after atazanavir exposure (2.3%) are not different from those noted for other antiretrovirals, nor from the reference population of the APR. As this is a voluntary registry, the number of anomalies found might be underreported.
Integrase inhibitors
Raltegravir is used in special cases during pregnancy only, that is in women presenting with HIV in late pregnancy with a high viral load or patients with no other options left. Recently, safety data on single and multiple cases were reported on regimens containing raltegravir as well as at least two other antiretrovirals [26,42 & ,43-46] . They all report a viral load decline of approximately 1 log/week, being very effective in reaching an undetectable viral load around delivery. In total, 22 cases were described, with one case of likely in utero MTCT (maternal viral load at delivery was 64 copies/ml, delivery by cesarean section). Most case reports did report raltegravir use to be well tolerated during pregnancy, except for one case of increased serum aminotransferases during pregnancy [45] . In this patient, after 11 days of treatment with raltegravir, a substantial reduction in viral load was achieved, but she had a 23-fold increase in serum ALAT and a 10-fold increase in serum ASAT. Both returned to normal upon raltegravir discontinuation. No congenital abnormalities were reported.
These articles suggest that raltegravir could be an option for women presenting with HIV late in pregnancy or having no treatment options left, being very effective in fast decreasing viral load. However, further studies are required to establish safety and pharmacokinetics of raltegravir during pregnancy.
CONCLUSION
Physiological changes during pregnancy show a general trend towards lower exposure to antiretrovirals, with the largest decrease for boosted protease inhibitors. Increased fraction of unbound concentrations does not seem to compensate completely for this decrease. However, virological failure or MTCT has not yet been associated with lower concentrations in pregnancy. This apparent discrepancy can be explained by the fact that the large majority of pregnant women harbour wild-type virus and antiretroviral C trough , even when reduced by 23-35%, remains in the therapeutic range for this specific group of patients. Increasing the dose of lopinavir and atazanavir has been shown to effectively compensate for decreased exposure during pregnancy. Increasing the dose can be done guided by TDM in the second and third trimester, in the presence of tenofovir (boosted atazanavir) and in particular when patients have a history of virological failure on a previous cART regimen. For newer compounds and efavirenz, limited or no data on pharmacokinetics during pregnancy or transplacentally are available.
The mechanisms of transplacental passage are not elucidated to date; further research on the role of transporters and placental metabolism is important to predict transplacental passage of new compounds. With regard to well tolerated use of antiretrovirals during pregnancy, monitoring of pregnancy outcomes in resource-limited setting during the implementation of the WHO guidelines, allowing efavirenz during pregnancy, with an emphasis on prematurity and congenital abnormalities, is important.
Raltegravir induces rapid viral decline during pregnancy and seems a fair option for women presenting with HIV in late pregnancy.
